litlas
ログインアカウント作成

David H. Kirn

1993–2024 年に発表

76
論文数
19,924
被引用数
73
h 指数
76
i10 指数

被引用数

David H. Kirn の年別被引用数1994 年: 被引用 1 件1995 年: 被引用 20 件1996 年: 被引用 51 件1997 年: 被引用 74 件1998 年: 被引用 87 件1999 年: 被引用 84 件2000 年: 被引用 183 件2001 年: 被引用 269 件2002 年: 被引用 269 件2003 年: 被引用 311 件2004 年: 被引用 222 件2005 年: 被引用 176 件2006 年: 被引用 161 件2007 年: 被引用 136 件2008 年: 被引用 160 件2009 年: 被引用 129 件2010 年: 被引用 135 件2011 年: 被引用 128 件2012 年: 被引用 138 件2013 年: 被引用 153 件2014 年: 被引用 163 件2015 年: 被引用 166 件2016 年: 被引用 144 件2017 年: 被引用 162 件2018 年: 被引用 147 件2019 年: 被引用 377 件2020 年: 被引用 445 件2021 年: 被引用 464 件2022 年: 被引用 325 件2023 年: 被引用 301 件2024 年: 被引用 384 件2025 年: 被引用 167 件2026 年: 被引用 9 件

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 1,427 件、この内訳の 35.7%中国: 引用元論文 411 件、この内訳の 10.3%イギリス: 引用元論文 294 件、この内訳の 7.4%カナダ: 引用元論文 245 件、この内訳の 6.1%ドイツ: 引用元論文 217 件、この内訳の 5.4%フランス: 引用元論文 128 件、この内訳の 3.2%イタリア: 引用元論文 122 件、この内訳の 3.1%日本: 引用元論文 103 件、この内訳の 2.6%スペイン: 引用元論文 89 件、この内訳の 2.2%オランダ: 引用元論文 89 件、この内訳の 2.2%韓国: 引用元論文 81 件、この内訳の 2%フィンランド: 引用元論文 65 件、この内訳の 1.6%
0%35.7%その他 18.2%

機関

分野

  • Biochemistry, Genetics and Molecular Biology65.4%
  • Medicine23.5%
  • Immunology and Microbiology7.3%
  • Agricultural and Biological Sciences0.6%
  • Engineering0.5%
  • Mathematics0.5%
  • その他2.2%

トピック

  • Virus-based gene therapy research18%
  • CAR-T cell therapy research10.2%
  • Cancer Research and Treatments5.3%
  • RNA Interference and Gene Delivery4.6%
  • Viral Infectious Diseases and Gene Expression in Insects4.5%
  • Immunotherapy and Immune Responses3.8%
  • その他53.6%

共著者

全論文

検索で開く
  1. Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies

    著者: Stephanie M. Salabarria, Manuela Corti, Kirsten E. Coleman, Megan B. Wichman, Julie Berthy, Precilla D’Souza, Cynthia J. Tifft, Roland W. Herzog, Melissa E. Elder, Lawrence R. Shoemaker, Carmen Leon‐Astudillo, Fatemeh Tavakkoli, David H. Kirn, Jonathan D. Schwartz, Barry J. Byrne - Journal of Clinical Investigation 2023 被引用: 128

  2. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer

    著者: Jeong Heo, Tony Reid, Leyo Ruo, Caroline J. Breitbach, Steven C. Rose, Mark Bloomston, Mong Cho, Ho Yeong Lim, Hyun Cheol Chung, Chang Won Kim, James M. Burke, Riccardo Lencioni, Theresa Hickman, Anne Moon, Yeon Sook Lee, Hyun Kyoung Kim, Manijeh Daneshmand, Kara Dubois, Lara Longpre, Minhtran Ngo, Cliona M. Rooney, John C. Bell, Byung-Geon Rhee, Richard H. Patt, Tae-Ho Hwang, David H. Kirn - Nature Medicine 2013 被引用: 776

  3. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans

    著者: Caroline J. Breitbach, James M. Burke, Derek J. Jonker, Joe Stephenson, Andrew R. Haas, Laura Q.M. Chow, Jorgé Nieva, Tae-Ho Hwang, Anne Moon, Richard H. Patt, Adina Pelusio, Fabrice Le Bœuf, Joe Burns, Laura Evgin, Naomi De Silva, Sara Cvancic, Terri Robertson, Ji-Eun Je, Yeon-Sook Lee, Kelley A. Parato, Jean‐Simon Diallo, Aaron Fenster, Manijeh Daneshmand, John C. Bell, David H. Kirn - Nature 2011 被引用: 550

  4. Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans

    著者: Caroline J. Breitbach, Rozanne Arulanandam, Naomi De Silva, Steve H. Thorne, Richard H. Patt, Manijeh Daneshmand, Anne Moon, Carolina S. Ilkow, James M. Burke, Tae-Ho Hwang, Jeong Heo, Mong Cho, Hannah Chen, Fernando A. Angarita, Christina Addison, J. Andrea McCart, John C. Bell, David H. Kirn - Cancer Research 2013 被引用: 253

  5. An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells

    著者: James R. Bischoff, David H. Kirn, Angelica Williams, Carla Heise, Sharon T. Horn, Mike Muna, Lelia Ng, Julie A. Nye, Adam Sampson-Johannes, Ali Fattaey, Frank McCormick - Science 1996 被引用: 1,762

  6. Targeting Tumor Vasculature With an Oncolytic Virus

    著者: Caroline J. Breitbach, Naomi S. De Silva, Theresa Falls, Usaf E. Aladl, Laura Evgin, Jennifer M Paterson, Yang Sun, Dominic G. Roy, Julia L. Rintoul, Manijeh Daneshmand, Kelley A. Parato, Marianne M. Stanford, Brian D. Lichty, Aaron Fenster, David H. Kirn, Harold Atkins, John C. Bell - Molecular Therapy 2011 被引用: 199

  7. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial

    著者: Byeong-Ho Park, Tae-Ho Hwang, Ta‐Chiang Liu, Daniel Y. Sze, Jae‐Seok Kim, Hyuk‐Chan Kwon, Sung Yong Oh, Sang‐Young Han, Jin-Han Yoon, Sook Hee Hong, Anne Moon, Kelly Speth, Chohee Park, Young‐joo Ahn, Manijeh Daneshmand, Byung Geon Rhee, Herbert M. Pinedo, John C. Bell, David H. Kirn - The Lancet Oncology 2008 被引用: 522

  8. Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)

    著者: Markus Moehler, Jeong Heo, H.C. Lee, Won Young Tak, Yee Chao, Seung Woon Paik, Hyung Joon Yim, Kwan Soo Byun, Ari David Baron, Guy Ungerechts, Derek J. Jonker, Leyo Ruo, Michael Cho, Andreas Kaubisch, Hennig Wege, Philippe Merle, Oliver Ebert, François Habersetzer, Jean‐Frédéric Blanc, Olivier Rosmorduc, Riccardo Lencioni, Richard H. Patt, Ann M. Leen, Friedrich Foerster, M. Homerin, Nicolas Stojkowitz, Monika Lusky, Jean‐Marc Limacher, Marie Hennequi, Nathalie Gaspar, B. McFadden, N. De Silva, Dongqi Shen, Adina Pelusio, David H. Kirn, Caroline J. Breitbach, James M. Burke - OncoImmunology 2019 被引用: 130

  9. The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers

    著者: Kelley A. Parato, Caroline J. Breitbach, Fabrice Le Boeuf, Jiahu Wang, Chris Storbeck, Carolina S. Ilkow, Jean‐Simon Diallo, Theresa Falls, Joseph K. Burns, Vanessa da Silva Garcia, Femina Kanji, Laura Evgin, Kang Hu, Francois Paradis, Shane Knowles, Tae-Ho Hwang, Barbara C. Vanderhyden, Rebecca C. Auer, David H. Kirn, John C. Bell - Molecular Therapy 2011 被引用: 308

  10. Preventing Postoperative Metastatic Disease by Inhibiting Surgery-Induced Dysfunction in Natural Killer Cells

    著者: Lee‐Hwa Tai, Christiano Tanese de Souza, Simon Bélanger, Lundi Ly, Almohanad A. Alkayyal, Jiqing Zhang, Julia L. Rintoul, Abhirami A. Ananth, Tiffany Lam, Caroline J. Breitbach, Theresa Falls, David H. Kirn, John C. Bell, Andrew P. Makrigiannis, Rebecca C. Auer - Cancer Research 2012 被引用: 238

  11. Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer

    著者: Se Hoon Park, Caroline J. Breitbach, Jeeyun Lee, Joon Oh Park, Ho Yeong Lim, Won Ki Kang, Anne Moon, Jae-Hee Mun, Erica M. Sommermann, Liliana Maruri Avidal, Rick Patt, Adina Pelusio, James M. Burke, Tae-Ho Hwang, David H. Kirn, Young Suk Park - Molecular Therapy 2015 被引用: 180

  12. VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection

    著者: Rozanne Arulanandam, Cory Batenchuk, Fernando A. Angarita, Kathryn Ottolino‐Perry, Sophie Cousineau, Amelia Mottashed, Emma Burgess, Theresa Falls, Naomi De Silva, Jovian Tsang, Grant A. Howe, Marie‐Claude Bourgeois‐Daigneault, David P. Conrad, Manijeh Daneshmand, Caroline J. Breitbach, David H. Kirn, Leda Raptis, Subash Sad, Harold Atkins, Michael S. Huh, Jean‐Simon Diallo, Brian D. Lichty, Carolina S. Ilkow, Fabrice Le Bœuf, Christina Addison, J. Andrea McCart, John C. Bell - Cancer Cell 2015 被引用: 104

  13. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer

    著者: David H. Kirn, Steve H. Thorne - Nature reviews. Cancer 2008 被引用: 411

  14. Phase 1 Study of Intratumoral Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus, in Pediatric Cancer Patients

    著者: Timothy P. Cripe, Minhtran Ngo, James I. Geller, Chrystal U. Louis, Mark A. Currier, John M. Racadio, Alexander J. Towbin, Cliona M. Rooney, Adina Pelusio, Anne Moon, Tae-Ho Hwang, James M. Burke, John C. Bell, David H. Kirn, Caroline J. Breitbach - Molecular Therapy 2014 被引用: 161

  15. First-in-man Study of Western Reserve Strain Oncolytic Vaccinia Virus: Safety, Systemic Spread, and Antitumor Activity

    著者: Herbert J. Zeh, Stephanie Downs‐Canner, J. Andrea McCart, Zong Sheng Guo, Uma N. M. Rao, Lekshmi Ramalingam, Stephen H. Thorne, Heather Jones, Paweł Kaliński, Eva Wieckowski, Mark E. O’Malley, Manijeh Daneshmand, Kang Hu, John C. Bell, Tae-Ho Hwang, Anne Moon, Caroline J. Breitbach, David H. Kirn, David L. Bartlett - Molecular Therapy 2014 被引用: 155

  16. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

    著者: Fadlo R. Khuri, John Nemunaitis, Ian Ganly, James C. Arseneau, Ian F. Tannock, L. Romel, Martin Gore, J. Ironside, R.H. MacDougall, Carla Heise, Britta Randlev, Ann M. Gillenwater, Patricia A. Bruso, Stanley B. Kaye, Waun Ki Hong, David H. Kirn - Nature Medicine 2000 被引用: 1,103

  17. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

    著者: Carla Heise, Adam Sampson-Johannes, Angelica Williams, Frank McCormick, Daniel D. Von Hoff, David H. Kirn - Nature Medicine 1997 被引用: 947

  18. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma.

    著者: J. Randolph Hecht, Rudolph A. Bedford, James L. Abbruzzese, Sandeep Lahoti, Tony R. Reid, Roy Soetikno, David H. Kirn, Sara M. Freeman - 2003 被引用: 496

  19. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress

    著者: Ta‐Chiang Liu, Evanthia Galanis, David H. Kirn - Nature Clinical Practice Oncology 2007 被引用: 450

  20. Sequential Therapy With JX-594, A Targeted Oncolytic Poxvirus, Followed by Sorafenib in Hepatocellular Carcinoma: Preclinical and Clinical Demonstration of Combination Efficacy

    著者: Jeong Heo, Caroline J. Breitbach, Anne Moon, Chang Won Kim, Rick Patt, Mi Kyung Kim, Yu Kyung Lee, Sung Yong Oh, Hyun Young Woo, Kelley A. Parato, Julia L. Rintoul, Theresa Falls, Theresa Hickman, Byung-Geon Rhee, John C. Bell, David H. Kirn, Tae-Ho Hwang - Molecular Therapy 2011 被引用: 146

  21. Oncolytic and Immunotherapeutic Vaccinia Induces Antibody-Mediated Complement-Dependent Cancer Cell Lysis in Humans

    著者: Mi Kyung Kim, Caroline J. Breitbach, Anne Moon, Jeong Heo, Yu Kyoung Lee, Mong Cho, Jun Woo Lee, Seong-Geun Kim, Dae Hwan Kang, John C. Bell, Byeong Ho Park, David H. Kirn, Tae-Ho Hwang - Science Translational Medicine 2013 被引用: 101

  22. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy

    著者: Carla Heise, Terry Hermiston, Leisa Johnson, Gabriel Brooks, Adam Sampson-Johannes, Angelica Williams, Lyndah Hawkins, David H. Kirn - Nature Medicine 2000 被引用: 585

  23. Systemic Armed Oncolytic and Immunologic Therapy for Cancer with JX-594, a Targeted Poxvirus Expressing GM-CSF

    著者: J.H. Kim, Joe Oh, B.H. Park, D.E. Lee, J.S. Kim, H.E. Park, Mee-Sook Roh, Ji-Eun Je, Jihyun Yoon, Steve H. Thorne, David H. Kirn, Tae-Ho Hwang - Molecular Therapy 2006 被引用: 304

  24. Targeted Inflammation During Oncolytic Virus Therapy Severely Compromises Tumor Blood Flow

    著者: Caroline J. Breitbach, Jennifer M Paterson, Chantal G. Lemay, Theresa Falls, Allison McGuire, Kelley A. Parato, David F. Stojdl, Manijeh Daneshmand, Kelly Speth, David H. Kirn, J. Andrea McCart, Harold Atkins, John C. Bell - Molecular Therapy 2007 被引用: 277